Targeting MYC-driven Lymphoma: Lessons Learned and Future Directions

Overview

Journal Cancer Drug Resist

Date 2023 Jul 17

PMID 37457123

Authors

Sandra Martinez-Martin

Marie-Eve Beaulieu

Laura Soucek

Affiliations

Soon will be listed here.

Abstract

MYC plays a central role in tumorigenesis by orchestrating cell proliferation, growth and survival, among other transformation mechanisms. In particular, MYC has often been associated with lymphomagenesis. In fact, MYC overexpressing lymphomas such as high-grade B-cell lymphoma (HGBL) and double expressor diffuse large B-cell lymphomas (DLBCL), are considered addicted to MYC. In such a context, MYC targeting therapies are of special interest, as MYC withdrawal is expected to result in tumor regression. However, whether high MYC levels are always predictive of increased sensitivity to these approaches is not clear yet. Even though no MYC inhibitor has received regulatory approval to date, substantial efforts have been made to investigate avenues to render MYC a druggable target. Here, we summarize the different classes of molecules currently under development, which mostly target MYC indirectly in aggressive B-cell lymphomas, paying special attention to subtypes with MYC/BCL2 or BCL6 translocations or overexpression.

Citing Articles

Investigating POU3F4 in cancer: Expression patterns, prognostic implications, and functional roles in tumor immunity.

Chen W, Ji Y, Wang R, Ji R, Lin Y, Wu Y Heliyon. 2025; 11(1):e41587.

PMID: 39866492 PMC: 11760290. DOI: 10.1016/j.heliyon.2024.e41587.

Delineating MYC-Mediated Escape Mechanisms from Conventional and T Cell-Redirecting Therapeutic Antibodies.

de Jonge A, Csikos T, Eken M, Bulthuis E, Poddighe P, Roemer M Int J Mol Sci. 2024; 25(22).

PMID: 39596160 PMC: 11594070. DOI: 10.3390/ijms252212094.

Lymphoma lurks within aged B cells.

Perez R, Jimenez-Martinez V, Martin-Subero J Nat Aging. 2024; 4(10):1343-1345.

PMID: 39349623 DOI: 10.1038/s43587-024-00714-z.

Expanded profiling of WD repeat domain 5 inhibitors reveals actionable strategies for the treatment of hematologic malignancies.

Meyer C, Smith B, Wang J, Teuscher K, Grieb B, Howard G Proc Natl Acad Sci U S A. 2024; 121(35):e2408889121.

PMID: 39167600 PMC: 11363251. DOI: 10.1073/pnas.2408889121.

MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer.

Casacuberta-Serra S, Gonzalez-Larreategui I, Capitan-Leo D, Soucek L Signal Transduct Target Ther. 2024; 9(1):205.

PMID: 39164274 PMC: 11336233. DOI: 10.1038/s41392-024-01907-z.

References

Aurer I, Dreyling M, Federico M, Tilly H, Linton K, Kimby E . Double Hit Lymphoma Diagnosis and Treatment in Europe-A Cross-Sectional Survey of Clinical Practice by the EHA Lymphoma Working Party (EHA LyG). Hemasphere. 2020; 4(6):e481. PMC: 7587423. DOI: 10.1097/HS9.0000000000000481. View

Shin N, Stubbs M, Koblish H, Yue E, Soloviev M, Douty B . Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase Inhibitor with Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell Malignancy. J Pharmacol Exp Ther. 2020; 374(1):211-222. DOI: 10.1124/jpet.120.265538. View

Cinar M, Rosenfelt F, Rokhsar S, Lopategui J, Pillai R, Cervania M . Concurrent inhibition of MYC and BCL2 is a potentially effective treatment strategy for double hit and triple hit B-cell lymphomas. Leuk Res. 2015; 39(7):730-8. DOI: 10.1016/j.leukres.2015.04.003. View

Sha C, Barrans S, Cucco F, Bentley M, Care M, Cummin T . Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy. J Clin Oncol. 2018; 37(3):202-212. PMC: 6338391. DOI: 10.1200/JCO.18.01314. View

Alaggio R, Amador C, Anagnostopoulos I, Attygalle A, de Oliveira Araujo I, Berti E . The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36(7):1720-1748. PMC: 9214472. DOI: 10.1038/s41375-022-01620-2. View

Luo C, Yu T, Young K, Yu L . HDAC inhibitor chidamide synergizes with venetoclax to inhibit the growth of diffuse large B-cell lymphoma via down-regulation of MYC, BCL2, and TP53 expression. J Zhejiang Univ Sci B. 2022; 23(8):666-681. PMC: 9381329. DOI: 10.1631/jzus.B2200016. View

Dhillon P, Evan G . In conversation with Gerard Evan. FEBS J. 2019; 286(24):4824-4831. DOI: 10.1111/febs.15121. View

Sonawane Y, Taylor M, Napoleon J, Rana S, Contreras J, Natarajan A . Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy. J Med Chem. 2016; 59(19):8667-8684. PMC: 5636177. DOI: 10.1021/acs.jmedchem.6b00150. View

Kang J, Zhang Y, Ding S, Yasheng K, Li Y, Yu Y . Modified conditioning regimen with chidamide and high-dose rituximab for triple-hit lymphoma. J Cell Mol Med. 2021; 25(22):10770-10773. PMC: 8581337. DOI: 10.1111/jcmm.16999. View

10.

Deng M, Shi Y, Chen K, Zhao H, Wang Y, Xie S . CS2164 exerts an antitumor effect against human Non-Hodgkin's lymphomas in vitro and in vivo. Exp Cell Res. 2018; 369(2):356-362. DOI: 10.1016/j.yexcr.2018.05.038. View

11.

Moreau P, Richardson P, Cavo M, Orlowski R, San Miguel J, Palumbo A . Proteasome inhibitors in multiple myeloma: 10 years later. Blood. 2012; 120(5):947-59. PMC: 4123429. DOI: 10.1182/blood-2012-04-403733. View

12.

Sesques P, Johnson N . Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements. Blood. 2016; 129(3):280-288. DOI: 10.1182/blood-2016-02-636316. View

13.

Zhuang Y, Che J, Wu M, Guo Y, Xu Y, Dong X . Altered pathways and targeted therapy in double hit lymphoma. J Hematol Oncol. 2022; 15(1):26. PMC: 8932183. DOI: 10.1186/s13045-022-01249-9. View

14.

Burke G, Beishuizen A, Bhojwani D, Burkhardt B, Minard-Colin V, Norris R . Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy. Leukemia. 2020; 34(8):2271-2275. PMC: 7387295. DOI: 10.1038/s41375-020-0749-5. View

15.

Khelfa Y, Lebowicz Y, Jamil M . Double-Hit Large B Cell Lymphoma. Curr Oncol Rep. 2017; 19(11):74. DOI: 10.1007/s11912-017-0629-y. View

16.

Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M . Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science. 2002; 297(5578):102-4. DOI: 10.1126/science.1071489. View

17.

Hann S . MYC cofactors: molecular switches controlling diverse biological outcomes. Cold Spring Harb Perspect Med. 2014; 4(9):a014399. PMC: 4143105. DOI: 10.1101/cshperspect.a014399. View

18.

Zhu J, Blenis J, Yuan J . Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1. Proc Natl Acad Sci U S A. 2008; 105(18):6584-9. PMC: 2373325. DOI: 10.1073/pnas.0802785105. View

19.

Nastoupil L, Neelapu S, Davis R, Samaniego F, Fowler N, Westin J . Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K β/δ in relapsed refractory B cell lymphoma. Leuk Lymphoma. 2021; 62(14):3452-3462. DOI: 10.1080/10428194.2021.1957874. View

20.

Soucek L, Whitfield J, Martins C, Finch A, Murphy D, Sodir N . Modelling Myc inhibition as a cancer therapy. Nature. 2008; 455(7213):679-83. PMC: 4485609. DOI: 10.1038/nature07260. View